{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:46Z","timestamp":1753891546337,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00230","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T04:41:37Z","timestamp":1552624897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke"],"prefix":"10.3389","volume":"10","author":[{"given":"Maren","family":"Hieber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Bardutzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke."},{"key":"B5","unstructured":"Akuttherapie des isch\u00e4mischen Schlaganfalls\u2013Erg\u00e4nzung 2015 Rekanalisierende Therapie, S2k-Leitlinie\n            RinglebPA\n            HamannGF\n            R\u00f6therJ\n            JansenO\n            GrodenC\n            VeltkampR\n          Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie.2015"},{"key":"B6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13256-016-1050-0","article-title":"Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report","volume":"10","author":"Gawehn","year":"2016","journal-title":"J Med Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/1747493017701944","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-A national case collection","volume":"12","author":"Kermer","year":"2017","journal-title":"Int J Stroke."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1161\/STROKEAHA.116.013550","article-title":"Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab","volume":"47","author":"Berrouschot","year":"2016","journal-title":"Stroke."},{"key":"B9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/acn3.346","article-title":"Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report","volume":"3","author":"Mutzenbach","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/ene.13582","article-title":"Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"25","author":"Touz\u00e9","year":"2018","journal-title":"Eur J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11239-018-1658-6","article-title":"Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients","volume":"46","author":"Hieber","year":"2018","journal-title":"J Thromb Thrombolysis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000447531","article-title":"Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report","volume":"8","author":"Kafke","year":"2016","journal-title":"Case Rep Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.006","article-title":"Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab - a case report","volume":"25","author":"Sch\u00e4fer","year":"2016","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jns.2009.02.323","article-title":"Acute ischemic stroke in anterior choroidal artery territory","volume":"281","author":"Ois","year":"2009","journal-title":"J Neurol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.09.015","article-title":"Thrombolytic therapy is an only determinant factor for stroke evolution in large anterior choroidal artery infarcts","volume":"23","author":"Wu","year":"2014","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.02.013","article-title":"Infarction in the anterior choroidal artery territory: clinical progression and prognosis factors","volume":"23","author":"Chausson","year":"2014","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00415-017-8410-6","article-title":"Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis","volume":"264","author":"Ng","year":"2017","journal-title":"J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1161\/STROKEAHA.118.022128","article-title":"Intravenous tPA (Tissue-Type Plasminogen Activator) inpatients with acute ischemic stroke taking non-vitamin K antagonist oral anticoagulants preceding stroke","volume":"49","author":"Jin","year":"2018","journal-title":"Stroke."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1747493016669849","article-title":"Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion","volume":"12","author":"Diener","year":"2017","journal-title":"Int J Stroke."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(10)60491-6","article-title":"Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials","volume":"375","author":"Lees","year":"2010","journal-title":"Lancet."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T04:41:46Z","timestamp":1552624906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":21,"alternative-id":["10.3389\/fneur.2019.00230"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00230","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"article-number":"230"}}